RG 7236
Alternative Names: RG7236Latest Information Update: 17 Apr 2012
At a glance
- Originator Roche
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 12 Apr 2012 Discontinued - Phase-I for Cardiovascular disorders in Switzerland (unspecified route)
- 02 Feb 2011 Phase-I clinical trials in cardiovascular risk reduction [Cardiovascular disorders - prevention] in patients with chronic kidney disease in Switzerland (unspecified route)